ID   LNCaP C4-2
AC   CVCL_4782
SY   LNCaP-C4-2; LNCaP subline C4-2; C4-2; C42; Sp 2817
DR   BTO; BTO_0005672
DR   ATCC; CRL-3314
DR   cancercelllines; CVCL_4782
DR   ChEMBL-Cells; CHEMBL4295439
DR   ChEMBL-Targets; CHEMBL4296460
DR   Cosmic; 1330914
DR   GEO; GSM3145590
DR   GEO; GSM3145694
DR   PubChem_Cell_line; CVCL_4782
DR   Wikidata; Q54902814
RX   PubMed=8169003;
RX   PubMed=15162376;
RX   PubMed=26499105;
RX   PubMed=29194687;
RX   PubMed=35502546;
WW   Info; CaP CLDb; -; https://web.archive.org/web/20150602153438/http://capcelllines.ca:80/details.asp?id=52
WW   Info; Thermo Fisher; -; https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-464.html
WW   Info; Wikipedia; -; https://en.wikipedia.org/wiki/LNCaP
CC   Population: Caucasian.
CC   Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice.
CC   Doubling time: ~24-36 hours (ATCC=CRL-3314); 28.96 hours (JWGray panel).
CC   Sequence variation: Mutation; HGNC; HGNC:644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=26499105).
CC   Sequence variation: Mutation; HGNC; HGNC:7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
ST   Source(s): PubMed=26499105
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10,11,12
ST   D13S317: 10,11,12
ST   D16S539: 10,11
ST   D5S818: 11,12
ST   D7S820: 9.1,9.3,10.3
ST   TH01: 9
ST   TPOX: 8,9
ST   vWA: 16,17,18
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4783 ! LNCaP C4
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 31
CH   CVCL_F0L4 ! LNCaP C4-2 AR-V7
CH   CVCL_F0L3 ! LNCaP C4-2 neo
CH   CVCL_4784 ! LNCaP C4-2B
CH   CVCL_6E92 ! LNCaP C4-2Ln
CH   CVCL_6E93 ! LNCaP C4-2Pr
//
RX   PubMed=15162376; DOI=10.1002/pros.20031;
RA   Liu, Alvin Y.
RA   Brubaker, Kristen D.
RA   Goo, Young Ah
RA   Quinn, Janna E.
RA   Kral, Sabine
RA   Sorensen, Carrie M.
RA   Vessella, Robert Louis
RA   Belldegrun, Arie S.
RA   Hood, Leroy Edward
RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer
RT   cell lines.";
RL   Prostate 60:98-108(2004).
//
RX   PubMed=29194687; DOI=10.1002/pros.23459; PMCID=PMC5768451;
RA   Fiandalo, Michael V.
RA   Wilton, John H.
RA   Mantione, Krystin M.
RA   Wrzosek, Carol
RA   Attwood, Kristopher M.
RA   Wu, Yue
RA   Mohler, James Larue
RT   "Serum-free complete medium, an alternative medium to mimic androgen
RT   deprivation in human prostate cancer cell line models.";
RL   Prostate 78:213-221(2018).
//
RX   PubMed=35502546; DOI=10.1158/0008-5472.CAN-22-1065; PMCID=PMC9153264;
RA   Abate-Shen, Cory
RA   Nunes de Almeida, Francisca
RT   "Establishment of the LNCaP cell line -- the dawn of an era for
RT   prostate cancer research.";
RL   Cancer Res. 82:1689-1691(2022).
//
RX   PubMed=8169003; DOI=10.1002/ijc.2910570319;
RA   Wu, Hsi-Chin
RA   Hsieh, Jer-Tsong
RA   Gleave, Martin E.
RA   Brown, Nicholas M.
RA   Pathak, Sen
RA   Chung, Leland W.K.
RT   "Derivation of androgen-independent human LNCaP prostatic cancer cell
RT   sublines: role of bone stromal cells.";
RL   Int. J. Cancer 57:406-412(1994).
//
RX   PubMed=26499105; DOI=10.1002/pros.23115; PMCID=PMC4729204;
RA   Castanares, Mark A.
RA   Copeland, Ben T.
RA   Chowdhury, Wasim H.
RA   Liu, Minzhi M.
RA   Rodriguez, Ronald
RA   Pomper, Martin G.
RA   Lupold, Shawn E.
RA   Foss, Catherine A.
RT   "Characterization of a novel metastatic prostate cancer cell line of
RT   LNCaP origin.";
RL   Prostate 76:215-225(2016).
//